Ramakrishnan Muthu, Kinsey Berma M, Singh Rana A, Kosten Thomas R, Orson Frank M
Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, 77030, TX, USA; Department of Medicine and Clinical Immunology, Baylor College of Medicine, Houston, 77030, TX, USA.
Chem Biol Drug Des. 2014 Sep;84(3):354-63. doi: 10.1111/cbdd.12326. Epub 2014 Jul 29.
In the absence of any effective pharmacotherapy for cocaine addiction, immunotherapy is being actively pursued as a therapeutic intervention. While several different cocaine haptens have been explored to develop anticocaine antibodies, none of the hapten was successfully designed, which had a protonated tropane nitrogen as is found in native cocaine under physiological conditions, including the succinyl norcocaine (SNC) hapten that has been tested in phase II clinical trials. Herein, we discuss three different cocaine haptens: hexyl norcocaine (HNC), bromoacetamido butyl norcocaine (BNC), and succinyl butyl norcocaine (SBNC), each with a tertiary nitrogen structure mimicking that of native cocaine which could optimize the specificity of anticocaine antibodies for better cocaine recognition. Mice immunized with these haptens conjugated to immunogenic proteins produced high titre anticocaine antibodies. However, during chemical conjugation of HNC and BNC haptens to carrier proteins, the 2β methyl ester group is hydrolyzed, and immunizing mice with these conjugate vaccines in mice produced antibodies that bound both cocaine and the inactive benzoylecgonine metabolite. While in the case of the SBNC conjugate, vaccine hydrolysis of the methyl ester did not appear to occur, leading to antibodies with high specificity to cocaine over BE. Although we observed similar specificity with a SNC hapten, the striking difference is that SBNC carries a positive charge on the tropane nitrogen atom, and therefore, it is expected to have better binding of cocaine. The 50% cocaine inhibitory concentration (IC50 ) value for SBNC antibodies (2.8 μm) was significantly better than the SNC antibodies (9.4 μm) when respective hapten-BSA was used as a substrate. In addition, antibodies from both sera had no inhibitory effect from BE. In contrast to BNC and HNC, the SBNC conjugate was also found to be highly stable without any noticeable hydrolysis for several months at 4 °C and 2-3 days in pH 10 buffer at 37 °C.
在缺乏针对可卡因成瘾的有效药物治疗方法的情况下,免疫疗法正作为一种治疗干预手段被积极探索。虽然已经研究了几种不同的可卡因半抗原以开发抗可卡因抗体,但没有一种半抗原被成功设计出来,这些半抗原都没有像生理条件下天然可卡因那样具有质子化的托烷氮,包括已在II期临床试验中测试过的琥珀酰去甲可卡因(SNC)半抗原。在此,我们讨论三种不同的可卡因半抗原:己基去甲可卡因(HNC)、溴乙酰氨基丁基去甲可卡因(BNC)和琥珀酰丁基去甲可卡因(SBNC),它们各自具有模仿天然可卡因的叔氮结构,这可以优化抗可卡因抗体的特异性以更好地识别可卡因。用这些与免疫原性蛋白质偶联的半抗原免疫的小鼠产生了高滴度的抗可卡因抗体。然而,在将HNC和BNC半抗原与载体蛋白进行化学偶联过程中,2β甲酯基团被水解,用这些偶联疫苗免疫小鼠产生的抗体既能结合可卡因,也能结合无活性的苯甲酰芽子碱代谢物。而对于SBNC偶联物,甲酯的疫苗水解似乎并未发生,从而产生了对可卡因比对苯甲酰芽子碱具有更高特异性的抗体。尽管我们观察到SNC半抗原具有相似的特异性,但显著的差异在于SBNC在托烷氮原子上带有正电荷,因此,预计它与可卡因的结合会更好。当使用各自的半抗原 - 牛血清白蛋白作为底物时,SBNC抗体的50%可卡因抑制浓度(IC50)值(2.8μm)明显优于SNC抗体(9.4μm)。此外,两种血清中的抗体对苯甲酰芽子碱均无抑制作用。与BNC和HNC不同,还发现SBNC偶联物高度稳定,在4°C下几个月没有明显水解,在37°C的pH 10缓冲液中2 - 3天也没有明显水解。